相关实验视频
Updated: Jun 27, 2025

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
43.7K
三甲素在改善内皮功能障碍中的作用:一篇评论
Yusof Kamisah1, Hamat H Che Hassan2
1Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
三甲素通过增强血管扩张和减少心血管疾病风险因素来改善内皮功能. 本综述探讨了其治疗内皮功能障碍和相关心脏病的机制.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 内皮功能障碍是心血管疾病的核心,导致血管扩张受损和动脉样硬化.
- 一种抗痛药物trimetazidine对内皮功能障碍表现出显著的治疗效果.
研究的目的:
- 审查三甲胺对内皮功能障碍的作用机制.
- 评估trimetazidine作为治疗心血管疾病的治疗剂的潜力.
主要方法:
- 对trimetazidine和内皮功能研究的文献综述.
- 对trimetazidine对氧化通路,炎症,氧化应激和动脉样硬化的影响的分析.
主要成果:
- 三甲素通过调节氧化合成酶和内甲素-1.1来增强血管扩张.
- 它改善了代谢参数,减少了氧化应激和炎症,并抑制了动脉样硬化.
- 三甲素调节了亡和血管生成,促进了内皮细胞的存活.
结论:
- 三甲胺表现出对内皮功能障碍有益的多方面的机制.
- 它作为治疗心血管疾病的治疗剂的潜力需要进一步的临床研究.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antihypertensive Drugs: Vasodilators
513
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
513
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
496
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
148
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
148
Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442

